872058-16-7

Upstream product

• 872058-15-6 2-amino-3-benzylthio-2-methylpropionamide 
• 15960-81-3 benzyl bromomethyl thioether 
• 191734-47-1 ((R)-2-Benzylsulfanyl-1-carbamoyl-1-methyl-ethyl)-carbamic acid benzyl ester 
• 143564-90-3 (2R,4R)-4-Benzylsulfanylmethyl-4-methyl-5-oxo-2-phenyl-oxazolidine-3-carboxylic acid benzyl ester 

Downstream Products

• 191734-57-3 {(S)-2-Benzylsulfanyl-1-[(R)-2-benzylsulfanyl-1-((R)-2-benzylsulfanyl-1-carbamoyl-1-methyl-ethylcarbamoyl)-1-methyl-ethylcarbamoyl]-1-methyl-ethyl}-carbamic acid benzyl ester 
• 154960-18-6 (R)-3-Benzylsulfanyl-2-[(R)-3-benzylsulfanyl-2-((S)-3-benzylsulfanyl-2-isobutyrylamino-2-methyl-propionylamino)-2-methyl-propionylamino]-2-methyl-propionamide 
• 191734-53-9 [(R)-2-Benzylsulfanyl-1-((R)-2-benzylsulfanyl-1-carbamoyl-1-methyl-ethylcarbamoyl)-1-methyl-ethyl]-carbamic acid benzyl ester 

Relevant academic research and scientific papers

NOVEL CRYSTAL MODIFICATIONS

Novel crystal modifications of (5S)-5-[4-(5-chloro-pyridin-2-yloxy)-piperidine-1-sulfonylmethyl]-5-methyl-imidazolidine-2,4-dione are disclosed together with processes for preparing such modifications, pharmaceutical compositions comprising such a modification, and the use of such a modification in therapy.

Convergent synthesis of (-)-mirabazole B using a chloroimidazolidium coupling reagent, CIP

(-)-Mirabazole B (1), an alkaloid consisting of four successive thiazoline/thiazole rings, has been synthesized in a convergent route. The key intermediate, a linear tripeptide amide 13 composing of three S-benzyl-2-methylcysteine residues, was prepared u